Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2015

Nitzan Rosenfeld's Biography



Nitzan Rosenfeld, Senior Group Leader, Cancer Research UK and CSO, Inivata Ltd.

Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science. In 2005 he joined Rosetta Genomics Limited, where he was head of Computational Biology and led development of molecular diagnostic tests. Since 2009 he is a group leader at the Cancer Research UK Cambridge Institute, now part of the University of Cambridge. His translational research group focuses on the application of circulating tumour DNA as a tool for cancer diagnostics and non-invasive genomics. In 2013 Nitzan was awarded the CRUK Future Leaders in Cancer Research prize, the British Association for Cancer Research Translational Research Award, and an ERC Starting Grant. In 2014, Nitzan and his colleagues founded Inivata, a clinical cancer genomics company that aims to harness the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.

Nitzan Rosenfeld Image

Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNA

Monday, 23 March 2015 at 12:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Novel biomarkers are required to accurately assess tumour burden and response in cancer.  Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA.  The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance.  Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment.  Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNA

Monday, 23 March 2015 at 12:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Novel biomarkers are required to accurately assess tumour burden and response in cancer.  Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA.  The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance.  Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment.  Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.

Noninvasive Cancer Genomics and Exploring Potential Clinical Applications of Circulating Tumor DNA

Monday, 23 March 2015 at 12:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Novel biomarkers are required to accurately assess tumour burden and response in cancer.  Circulating tumour DNA (ctDNA), containing tumour-specific DNA alterations, is present in patient plasma as a fraction of the total cell-free DNA.  The study of ctDNA levels and mutational profile could potentially inform clinical decision making, be used to monitor tumour dynamics, assess response to treatment and identify mutations associated with acquired drug resistance.  Inivata is a clinical cancer genomics company focused on harnessing the emerging potential of circulating DNA analysis to improve cancer testing and treatment.  Novel applications of ctDNA are enabled by Inivata’s technology platform which includes its proprietary enhanced TAm-Seq™ technology, to allow the detection and analysis of genomic material from a cancer patient’s cell-free DNA collected through routinely accessible blood samples. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.


Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonCirculating Biomarkers World Congress 2015Circulating Biomarkers World Congress 2015 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com